Loading clinical trials...

Prebiotic Effect on Metabolites in Crohn's Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Prebiotic Effect on Metabolites in Crohn's Disease

Metabolite Profiling of the Impact of Oligofructose Enriched Inulin in Crohn's Disease Patients

NCT01487759•KU Leuven

Summary

The purpose of this study is to investigate the influence of the prebiotic oligofructose enriched inulin on the metabolite pattern in Crohn's disease patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•crohn's disease

Exclusion Criteria

•severe crohn's disease (harvey bradshaw index \>12)
•pregnancy
•history of colectomy
•use of antibiotics 4-wks before start of the study
•use of sulfapyridine
•use of commercially available prebiotics and probiotics

Locations (1)

KULeuven

Leuven, Belgium

Key Dates

Start Date

March 1, 2008

Completion Date

July 1, 2009

Last Updated

December 12, 2011

Enrollment

ACTUAL participants

Conditions

Crohn Disease

Interventions

Oligofructose enriched inulin

DIETARY_SUPPLEMENT

Maltodextrin

DIETARY_SUPPLEMENT

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prebiotic Effect on Metabolites in Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study